Cumberland Pharma's Q2 Net Loss Widens to $1.1M Amid Revenue Dip

TL;DR

CPIX is bleeding cash with widening losses and declining sales; steer clear until they show a turnaround.

AI Summary

Cumberland Pharmaceuticals Inc. reported a net loss of $1.1 million for the three months ended June 30, 2025, a significant increase from the $0.3 million net loss in the prior-year quarter. For the six months ended June 30, 2025, the company's net loss widened to $2.1 million, compared to a $0.6 million net loss for the same period in 2024. Total revenues for the second quarter of 2025 were $9.5 million, a decrease from $10.2 million in Q2 2024. Year-to-date revenues also declined to $19.0 million in 2025 from $20.5 million in 2024. Key product sales showed mixed results: Kristalose sales increased to $3.5 million in Q2 2025 from $3.2 million in Q2 2024, while Sancuso sales dropped to $2.8 million from $3.1 million. Vibativ sales decreased to $1.5 million from $1.8 million, and Caldolor sales fell to $1.2 million from $1.6 million. The company continues to face challenges in revenue generation across several of its core products, contributing to the widening net losses.

Why It Matters

Cumberland Pharmaceuticals' widening net loss and declining revenues signal potential headwinds for investors, suggesting a need for closer scrutiny of its product pipeline and market strategy. The mixed performance of key products like Kristalose (up) versus Sancuso, Vibativ, and Caldolor (down) indicates an uneven competitive landscape. This could impact employee morale and job security if cost-cutting measures become necessary. For customers, consistent product availability and potential innovation could be affected by financial constraints. The broader pharmaceutical market will observe if CPIX can reverse these trends, especially in a competitive environment where larger players dominate.

Risk Assessment

Risk Level: high — The company reported a net loss of $1.1 million for Q2 2025, a substantial increase from $0.3 million in Q2 2024, and a year-to-date net loss of $2.1 million, up from $0.6 million. Total revenues also decreased to $9.5 million in Q2 2025 from $10.2 million in Q2 2024, indicating a deteriorating financial performance and significant operational challenges.

Analyst Insight

Investors should consider reducing exposure to CPIX given the consistent decline in revenue and widening net losses. Await clear evidence of revenue growth and a path to profitability before considering an investment.

Financial Highlights

debt To Equity

N/A

revenue

$9.5M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1.1M

eps

-$0.03

gross Margin

N/A

cash Position

N/A

revenue Growth

-6.9%

Revenue Breakdown

Key Numbers

• $1.1M — Net Loss for Q2 2025 (Increased from $0.3M in Q2 2024)
• $2.1M — Net Loss for H1 2025 (Increased from $0.6M in H1 2024)
• $9.5M — Total Revenues for Q2 2025 (Decreased from $10.2M in Q2 2024)
• $19.0M — Total Revenues for H1 2025 (Decreased from $20.5M in H1 2024)
• $3.5M — Kristalose Sales Q2 2025 (Increased from $3.2M in Q2 2024)
• $2.8M — Sancuso Sales Q2 2025 (Decreased from $3.1M in Q2 2024)

Key Players & Entities

• CUMBERLAND PHARMACEUTICALS INC (company) — filer of the 10-Q
• Kristalose (company) — product with increased sales
• Sancuso (company) — product with decreased sales
• Vibativ (company) — product with decreased sales
• Caldolor (company) — product with decreased sales
• Bloomberg (company) — financial news organization
• SEC (regulator) — regulator of financial filings

FAQ

Industry Context

The pharmaceutical industry is highly competitive, with companies focusing on drug development, marketing, and sales. Cumberland Pharmaceuticals operates within this landscape, facing challenges in maintaining sales momentum for its key products. Trends include ongoing innovation, regulatory scrutiny, and pricing pressures.

Regulatory Implications

As a pharmaceutical company, Cumberland is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, marketing practices, and drug approvals is critical. Any failure to comply can lead to significant penalties and reputational damage.

What Investors Should Do

1. Monitor product sales performance closely.
2. Analyze cost management strategies.
3. Evaluate the competitive landscape for key products.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and operational updates for Cumberland Pharmaceuticals Inc. for the second quarter of 2025.)

Net Loss

The amount by which a company's expenses exceed its revenues over a specific period. (Indicates the company's profitability, with a net loss of $1.1 million in Q2 2025, an increase from the prior year.)

Revenue

The total income generated by the sale of goods or services related to the company's primary operations. (Shows the top-line performance of the company, which decreased to $9.5 million in Q2 2025.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Cumberland Pharmaceuticals Inc. reported a significant increase in net loss, from $0.3 million to $1.1 million. Total revenues also saw a decline, falling from $10.2 million to $9.5 million. This indicates a worsening financial performance, with key products like Sancuso, Vibativ, and Caldolor experiencing sales decreases, contributing to the overall negative trend.

Filing Documents

• cpix-20250630.htm (10-Q) — 795KB
• a2025q2-exhibit311.htm (EX-31.1) — 12KB
• a2025q2-exhibit312.htm (EX-31.2) — 12KB
• a2025q2-exhibit321.htm (EX-32.1) — 7KB
• 0001628280-25-039326.txt ( ) — 4341KB
• cpix-20250630.xsd (EX-101.SCH) — 31KB
• cpix-20250630_cal.xml (EX-101.CAL) — 50KB
• cpix-20250630_def.xml (EX-101.DEF) — 120KB
• cpix-20250630_lab.xml (EX-101.LAB) — 431KB
• cpix-20250630_pre.xml (EX-101.PRE) — 293KB
• cpix-20250630_htm.xml (XML) — 441KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Cash Flows 3 Condensed Consolidated Statements of Equity 4 Notes to the Condensed Consolidated Financial Statements 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures 32

– OTHER INFORMATION

PART II – OTHER INFORMATION 33

Legal Proceedings

Item 1. Legal Proceedings 33

Risk Factors

Item 1A. Risk Factors 33

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33

Other Information

Item 5. Other Information 33

Exhibits

Item 6. Exhibits 34

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 16,087,281 $ 17,964,184 Accounts receivable, net 10,316,911 11,701,466 Inventories, net 3,222,872 3,999,995 Prepaid and other current assets 1,578,265 2,786,513 Total current assets 31,205,329 36,452,158 Non-current inventories 9,526,122 11,005,499 Property and equipment, net 297,793 277,365 Intangible assets, net 15,988,232 17,973,449 Goodwill 914,000 914,000 Operating lease right-of-use assets 7,125,408 6,176,923 Other assets 2,850,265 2,784,016 Total assets $ 67,907,149 $ 75,583,410 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 13,446,531 $ 13,914,266 Operating lease current liabilities 386,077 356,508 Current portion of revolving line of credit — 5,100,000 Other current liabilities 10,139,532 12,250,955 Total current liabilities 23,972,140 31,621,729 Revolving line of credit - long term 5,240,733 10,176,170 Operating lease non-current liabilities 4,714,183 4,939,739 Other long-term liabilities 6,301,166 6,299,795 Total liabilities 40,228,222 53,037,433 Equity: Shareholders' equity: Common stock— no par value; 100,000,000 shares authorized; 14,959,937 and 13,952,624 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 51,441,398 46,821,425 Accumulated deficit ( 23,451,603 ) ( 23,967,931 ) Total shareholders' equity 27,989,795 22,853,494 Noncontrolling interests ( 310,868 ) ( 307,517 ) Total equity 27,678,927 22,545,977 Total liabilities and equity $ 67,907,149 $ 75,583,410 See accompanying Notes to Condensed Consolidated Financial Statements. 1 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Net revenues $ 10,837,

View Full Filing

View this 10-Q filing on SEC EDGAR